📊 BNTC Key Takeaways
Is Benitec Biopharma Inc. (BNTC) a Good Investment?
Benitec Biopharma is a pre-revenue stage biopharmaceutical company with no commercial revenue and significant ongoing operating losses of $23.2M, indicating the company is in early-stage development without approved products generating sales. While the company maintains a strong cash position of $188.8M with minimal debt, the current burn rate of $7.1M in negative operating cash flow combined with zero revenue sustainability suggests the company has several years of runway but faces existential risk if development programs fail to advance successfully.
Benitec Biopharma's fundamentals reflect a pre-revenue biotech with no operating income, recurring net losses, and negative free cash flow, so profitability quality is currently weak. The counterbalance is an exceptionally strong balance sheet, with cash exceeding total liabilities by a wide margin and essentially no leverage, which provides meaningful runway to fund development. Overall, the company appears financially secure in the near term but still fundamentally dependent on future clinical and commercialization progress rather than current operating performance.
Why Buy Benitec Biopharma Inc. Stock? BNTC Key Strengths
- Exceptionally strong liquidity position with $188.8M in cash and 67.69x current ratio
- Zero debt burden providing financial flexibility for R&D investments
- Substantial stockholders equity of $187.4M backing the balance sheet
- Minimal liabilities at only $3.3M relative to total assets
- Exceptionally strong liquidity, with $188.79M in cash and current and quick ratios of 67.69x
- Minimal balance sheet risk, with only $3.32M in liabilities and effectively no debt
- Large equity base of $187.36M provides financial flexibility to absorb ongoing losses
BNTC Stock Risks: Benitec Biopharma Inc. Investment Risks
- Complete absence of revenue generation indicating pre-commercialization stage with uncertain pipeline success
- Negative operating cash flow of $7.1M annually representing unsustainable cash burn without product approval
- Negative ROE of -11.1% and ROA of -10.9% showing value destruction for shareholders
- Pharmaceutical development risk where pipeline candidates may fail clinical trials or regulatory approval
- Extended timeline to potential profitability dependent on successful product development and market adoption
- No revenue base means the business currently lacks proven commercial traction
- Operating loss of $23.18M and negative free cash flow of $7.14M indicate continued cash burn
- Returns on equity and assets are negative, showing capital is not yet producing profitable outcomes
Key Metrics to Watch
- Operating cash burn rate and cash runway months remaining
- Clinical trial progression and regulatory milestones for pipeline candidates
- Total revenue upon first product commercialization and gross margins
- Operating expense trajectory and cash burn deceleration
- Insider transactions and capital raises indicating management confidence or dilution concerns
- Quarterly operating cash burn relative to cash reserves
- Any transition from pre-revenue status toward sustainable revenue generation
Benitec Biopharma Inc. (BNTC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 67.69x current ratio provides a solid financial cushion.
BNTC Profit Margin, ROE & Profitability Analysis
BNTC vs Healthcare Sector: How Benitec Biopharma Inc. Compares
How Benitec Biopharma Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Benitec Biopharma Inc. Stock Overvalued? BNTC Valuation Analysis 2026
Based on fundamental analysis, Benitec Biopharma Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Benitec Biopharma Inc. Balance Sheet: BNTC Debt, Cash & Liquidity
BNTC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Benitec Biopharma Inc.'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $-1.22 indicates the company is currently unprofitable.
BNTC Revenue Growth, EPS Growth & YoY Performance
BNTC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | N/A | -$5.1M | $-0.48 |
| Q3 2024 | N/A | -$4.3M | $-1.64 |
| Q2 2024 | N/A | -$5.1M | $-0.33 |
| Q3 2023 | $48.0K | -$3.3M | $-0.16 |
| Q2 2023 | $14.0K | -$4.8M | $-0.20 |
| Q1 2023 | N/A | -$5.0M | $-0.47 |
| Q3 2022 | $1.0K | -$2.7M | N/A |
| Q2 2022 | $1.0K | -$2.7M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Benitec Biopharma Inc. Dividends, Buybacks & Capital Allocation
BNTC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Benitec Biopharma Inc. (CIK: 0001808898)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BNTC
What is the AI rating for BNTC?
Benitec Biopharma Inc. (BNTC) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BNTC's key strengths?
Claude: Exceptionally strong liquidity position with $188.8M in cash and 67.69x current ratio. Zero debt burden providing financial flexibility for R&D investments. ChatGPT: Exceptionally strong liquidity, with $188.79M in cash and current and quick ratios of 67.69x. Minimal balance sheet risk, with only $3.32M in liabilities and effectively no debt.
What are the risks of investing in BNTC?
Claude: Complete absence of revenue generation indicating pre-commercialization stage with uncertain pipeline success. Negative operating cash flow of $7.1M annually representing unsustainable cash burn without product approval. ChatGPT: No revenue base means the business currently lacks proven commercial traction. Operating loss of $23.18M and negative free cash flow of $7.14M indicate continued cash burn.
What is BNTC's revenue and growth?
Benitec Biopharma Inc. reported revenue of $0.0.
Does BNTC pay dividends?
Benitec Biopharma Inc. does not currently pay dividends.
Where can I find BNTC SEC filings?
Official SEC filings for Benitec Biopharma Inc. (CIK: 0001808898) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BNTC's EPS?
Benitec Biopharma Inc. has a diluted EPS of $-0.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BNTC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Benitec Biopharma Inc. has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BNTC stock overvalued or undervalued?
Valuation metrics for BNTC: ROE of -11.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BNTC stock in 2026?
Our dual AI analysis gives Benitec Biopharma Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BNTC's free cash flow?
Benitec Biopharma Inc.'s operating cash flow is $-7.1M, with capital expenditures of $11.0K.
How does BNTC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -11.1% (avg: 15%), current ratio 67.69 (avg: 2).